Redeye’s first comments on CellaVision’s report for Q2. The report showed sales slightly higher at SEK 118m vs our expectations of SEK 115m. However, the gross margin was a tad lower at 66% compared with the 68% expected. We still have a positive long-term view and believe that short-term dips can provide good opportunities to buy the share.